Karuna Therapeutics, Inc. Stock News

Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Bristol Myers Squibb (BMY) is buying biopharmaceutical company Karuna Therapeutics (KRTX) for $330.00 per share, with the deal valued at $14 billion. Karuna has an experimental schizophrenia drug that

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Karuna (NASDAQ: KRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol-Myers. Cl

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.

Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

CNBC's Joe Kernen reports on the latest news.

Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.

Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% has r

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. A final decision is expected in September 2024.

Karuna Therapeutics focuses on developing therapies that target muscarinic cholinergic receptors to treat psychosis and cognitive impairment in CNS disorders. The Company's lead asset, KarXT, has show

Karuna Therapeutics, Inc. (NASDAQ:KRTX ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Alexis Smith - Head of Corporate Affairs and IR Bill Meury - President and CE

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.